These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 34329792)

  • 1. In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018.
    Gant V; Hussain A; Bain M; Longshaw C; Henriksen AS
    J Glob Antimicrob Resist; 2021 Dec; 27():1-11. PubMed ID: 34329792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014-2018 studies in Spain.
    Cercenado E; Cardenoso L; Penin R; Longshaw C; Henriksen AS; Pascual A
    J Glob Antimicrob Resist; 2021 Sep; 26():292-300. PubMed ID: 34274538
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Naas T; Lina G; Santerre Henriksen A; Longshaw C; Jehl F
    JAC Antimicrob Resist; 2021 Jun; 3(2):dlab081. PubMed ID: 34223140
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Shortridge D; Streit JM; Mendes R; Castanheira M
    Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0199021. PubMed ID: 34807757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Italy.
    Stracquadanio S; Torti E; Longshaw C; Henriksen AS; Stefani S
    J Glob Antimicrob Resist; 2021 Jun; 25():390-398. PubMed ID: 34020073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy.
    Bassetti M; Monti G; Henriksen AS; Longshaw C
    Antimicrob Resist Infect Control; 2024 Aug; 13(1):91. PubMed ID: 39183351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
    Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Santerre Henriksen A; Jeannot K; Oliver A; Perry JD; Pletz MW; Stefani S; Morrissey I; Longshaw C;
    Microbiol Spectr; 2024 Apr; 12(4):e0383623. PubMed ID: 38483164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany.
    Thelen P; Henriksen AS; Longshaw C; Yamano Y; Caldwell B; Hamprecht A
    J Glob Antimicrob Resist; 2022 Mar; 28():12-17. PubMed ID: 34920174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
    J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance.
    Kayama S; Kawakami S; Kondo K; Kitamura N; Yu L; Hayashi W; Yahara K; Sugawara Y; Sugai M
    J Glob Antimicrob Resist; 2024 Sep; 38():12-20. PubMed ID: 38789082
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium.
    Oueslati S; Bogaerts P; Dortet L; Bernabeu S; Ben Lakhal H; Longshaw C; Glupczynski Y; Naas T
    Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.
    Karakonstantis S; Rousaki M; Vassilopoulou L; Kritsotakis EI
    Clin Microbiol Infect; 2024 Feb; 30(2):178-188. PubMed ID: 37666449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of Cefiderocol Against
    Iregui A; Khan Z; Landman D; Quale J
    Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
    Simner PJ; Patel R
    J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32727829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.